<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31865">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017418</url>
  </required_header>
  <id_info>
    <org_study_id>2012-10531</org_study_id>
    <nct_id>NCT02017418</nct_id>
  </id_info>
  <brief_title>The Effects of a Zeaxanthin Intervention on Visuomotor Function</brief_title>
  <official_title>The Effects of a Zeaxanthin Intervention on Visuomotor Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZeaVision, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Georgia</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test whether two zeaxanthin formulations (supplements containing
      different nutritional compounds with zeaxanthin and omega fatty acids being the primary
      ingredients of interest) influenced visual motor function.  Visual motor function refers to
      the processing speed of the visual system and how individuals respond behavioral to visual
      stimuli (e.g., reaction time).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Macular pigment optical density</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increases in the amount of macular pigment measured in optical density units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fixed reaction time</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>reaction time to a stimulus fixed in space</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variable reaction time</measure>
    <time_frame>12-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>reaction time to a stimulus with a position that varies in space</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coincidence anticipation</measure>
    <time_frame>12-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>button press when a light stimulus of varying speeds reaches a specific point in a linear light array</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Behavior and Behavior Mechanisms</condition>
  <arm_group>
    <arm_group_label>zeaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo zeaxanthin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combinatory supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo combinatory supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zeaxanthin</intervention_name>
    <arm_group_label>zeaxanthin</arm_group_label>
    <other_name>zeaxanthin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>combinatory supplement</intervention_name>
    <arm_group_label>combinatory supplement</arm_group_label>
    <other_name>zeaxanthin + lutein + DHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: ≥18 and ≤ 40 years

          -  BMI: ≥ 20 and ≤ 30 kg/m2

          -  No anticipated changes in dieting habits (as relevant to the intake of xanthophylls
             and fats/oils).

          -  No anticipated surgical procedures.

          -  Willingness and ability to give written informed consent and willingness and ability
             to comply with the study requirements.

          -  Corrected visual acuity (ETDRS): better than 20/60 in the eye selected for the study

        Exclusion Criteria:

          -  Smokers

          -  Current or history of relevant ocular diseases (such as AMD) or other conditions
             e.g., lipid disorders.

          -  Inability to reliably perform macular pigment optical density measurements by
             &quot;Heterochromatic Flicker Photometry&quot; or any of the other ophthalmic tests of the
             study.

          -  Any condition likely to interfere with normal gastro-intestinal absorption of
             xanthophylls (e.g., digestive disorders: inflammatory bowel disease, ulcerative
             colitis, Crohn's, irritable bowel, etc. or lipid disorders including conditions such
             as hypercholesterolemia)

          -  Current use of xanthophyll containing supplements or use of xanthophyll containing
             supplements in the past 6 months (but excluding multivitamins containing lutein or
             zeaxanthin at low potency).

          -  Participation in any other study during last 1 month before study initiation.

          -  Known hypersensitivity or allergy to xanthophylls.

          -  Regular intake of medications or supplements, which the principal investigator deems
             likely to confound the study outcomes. These include diabetes medication and statins
             or any other drug/supplement to modulate cholesterol or fat digestion/absorption.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy R Hammond, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Georgia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Billy R Hammond, Ph.D.</last_name>
    <phone>706-542-4812</phone>
    <email>bhammond@uga.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily R Bovier, M.S</last_name>
    <phone>706-542-4812</phone>
    <email>erbovier@uga.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychology, UGA</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy R Hammond, Ph.D.</last_name>
      <phone>706-542-4812</phone>
      <email>bhammond@uga.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily R Bovier, Ph.D.</last_name>
      <phone>706-542-4812</phone>
      <email>erbovier@uga.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Georgia</investigator_affiliation>
    <investigator_full_name>Billy R. Hammond</investigator_full_name>
    <investigator_title>Professor and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>zeaxanthin</keyword>
  <keyword>visual function</keyword>
  <keyword>reaction time</keyword>
  <keyword>processing speed</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
